[en] OBJECTIVE: To compare the effects on endometrium, climacteric symptoms and the menstrual cycle, and the clinical and biological tolerance of two percutaneous oestradiol gels used as hormone replacement therapy. DESIGN: A large open randomised multicentre study. SETTING: France and Belgium. PARTICIPANTS: Two-hundred and fifty-four women with an intact uterus and who had experienced a natural menopause received either Oestrogel (n = 126) or Estreva, a new formulation of oestradiol gel (n = 128), (1.5 mg of oestradiol/day) for the 24 first days of each calendar month during six consecutive months. Nomegestrol acetate (Lutenyl), a norprogesterone derivative, was administered (5 mg/day) from day 11 to day 24 of each oestradiol cycle. MAIN OUTCOME MEASURES: Examination of endometrial biopsies taken before treatment and between days 18 and 24 of the last treatment cycle, climacteric symptoms assessed using a modified Kupperman index, control of menstrual cycle evaluated by diary cards, and clinical and biological tolerance. RESULTS: Both treatments lowered the frequency and intensity of hot flushes and the global Kupperman index. 96% of the cycles were followed by withdrawal bleeding. Breakthrough bleeding or spotting resulted in premature discontinuation of treatment in one volunteer. Mastodynia occurred in 20 women and contributed to the premature termination of treatment in three of them. Endometrial biopsies taken at the end of treatment showed identical histologies in both groups, with a secretory pattern in the majority of women, and absence of hyperplasia. CONCLUSIONS: This trial confirmed that, when the two oestradiol gels tested were administered cyclically with nomegestrol acetate to postmenopausal women, they were well tolerated, effective and suitable for the treatment of oestrogen deficiency syndrome.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement
Sitruk-Ware R, De Lignières B, Basdevant A, Mauvais-Jarvis P. Absorption of percutaneous oestradiol in postmenopausal women. Maturitas 1980; 2: 207–211.
Lyrenas S, Carlstrom K, Backstrom T, von Schoultz B. A comparison of serum oestrogen levels after percutaneous and oral administration of oestradiol-17β. Br J Obstet Gynaecol 1981; 88: 181–187.
Fahraeus L, Larsson-Cohn U. Oestrogens, gonadotrophins and SHBG during oral and cutaneous administration of oestradiol-17β to menopausal women. Acta Endocrinol 1982; 101: 592–596.
Holst J, Cajander S, Carlstrom K, Damber MG, von Schoultz B. Percutaneous oestrogen therapy opposed by lynestrenol or natural progesterone—effects on circulating oestrogens, FSH, sex hormone binding globulin and pregnancy zone protein. Maturitas 1983; 5: 1–8.
Hassager C, Riis BJ, Strom V, Guyene TT, Christiansen C. The long term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987; 76: 753–758.
Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987; 156: 66–71.
Faguer de Moustier B, Conard J, Guyene TT et al. Comparative metabolic study of percutaneous versus oral micronized 17β-oestradiol in replacement therapy. Maturitas 1989; 11: 275–286.
Basdevant A, De Lignières B, Simon P, Blache D, Ponsin G, Guy-Grand B. Hepatic lipase activity during oral and parenteral 17β-estradiol replacement therapy: High-density lipoprotein increase may not be antiatherogenic. Fertil Steril 1991; 55: 1112–1117.
Basdevant A, Pelissier C, Conard J, Degrelle H, Guyene TT, Thomas JL. Effects of nomegestro! acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991; 44: 599–605.
Dupont A, Dupont P, Cusan L et al. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991; 13: 297–311.
Sturdee DW, Barlow DH, Ulrich LG et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy Lancet 1994; 343: 979–982.
Dorangeon P, Thomas JL, Gillery P, Lumbroso M, Hazard MC. Short term effects on lipids and lipoproteins of two progestogens used in postmenopausal replacement therapy. Eur J Clin Res 1992; 3: 187–193.
Dorangeon P, Thomas JL, Choisy H, Lumbroso M, Hazard MC. Effects of nomegestrol acetate on carbohydrate metabolism. Diabete Metab 1993; 19: 441–445.
Conard J, Basdevant A, Thomas JL et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: A placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995; 64: 957–962.
Massai MR, Bergeron C, Martel D et al. Physiological oestradiol and progesterone replacement cycles in women with ovarian failure: A model to study endometrial maturation and sex steroid receptor regulation by exogenous hormones. Human Reprod 1993; 8: 1828–1834.
Kupperman HS, Wetchler BB, Blatt MHG. Contemporary therapy of the menopausal syndrome. JAMA 1959; 171: 1627–1637.
Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–277.
Thomas JL, Bernard AM, Denis C. Postmenopausal hormone replacement therapy with estrogens and nomegestrol acetate: A multicentric study. Proceedings of the VIIth International Congress on The Menopause; 1993 June 2024; Stockholm, Sweden [abstract 372].
Holst J, Cajander S, Schoultz B. Endometrial response in post-menopausal women during treatment with percutaneous 17β-oestradiol opposed by oral progesterone. Maturitas 1986; 8: 201–207.
Herendael BJ, Bulck B, Bettocchi S, Stuyck J, Vereecken A. Endometrial response to percutaneous estradiol combined with low-dose oral micronized progesterone: Hysteroscopic aspects. In: Dusitsin N, Notelovitz M, editors. Physiological Hormone Replacement Therapy. Carnforth, UK : The Parthenon Group, 1991: 73–78.
Figueroa-Casas PR, Schlaen I. Sequential use of conjugated estrogens and medroxyprogesterone in the climacteric syndrome: Clinical and histological findings. Maturitas 1988; 9: 309–313.
Koninckx PR, Lauweryns JM, Cornillie FJ. Endometrial effects during hormone replacement therapy with a sequential oestradiol valerate/cyproterone acetate preparation. Maturitas 1993; 16: 97–110.
Ross AH, Boyd ME, Colgan TJ, Ferenczy A, Fugere P, Lorrain J. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: Effects on bleeding patterns and endometrial histology. Obstet Gynecol 1993; 82: 773–779.
Saure A, Hirvonen E, Tikkanen MJ, Viinikka L, Ylikorkala O. A novel oestradiol-desogestrel preparation for hormone replacement therapy: Effects on hormones, lipids, bone, climacteric symptoms and endometrium. Maturitas 1993; 16: 1–12.
Hoist J, Cajander S, von Schoultz B. Endometrial effects of a continuous percutaneous oestrogen/low dose oral progestogen regimen for climacteric complaints. Maturitas 1987; 9: 63–67.
Moyer DL, De Lignières B, Driguez P, Fez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: Influence of bleeding pattern and secretory changes. Fertil Steril 1993; 59: 992–997.